Study of two new drugs for first-time liver cancer treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two investigational drugs (PM8002 and PM1009) as a first treatment for advanced liver cancer that cannot be surgically removed. The goal is to see if this new treatment works better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have liver cancer (HCC) that cannot be removed by surgery or has spread to other parts of the body.
- Your liver function is good (Child-Pugh score of 7 or less).
- You have not had any prior whole-body cancer treatment for advanced liver cancer.
- You have at least one tumor that can be seen and measured on a scan.
- You are in good overall health (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (rilvegostomig plus bevacizumab, with or without tremelimumab) as a first treatment for people with advanced liver cancer (HCC) that cannot be removed by surgery or treated with local therapies. It aims to see if these combinations help shrink tumors or slow disease progression.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This Phase 1/2 study tests new combinations of immune system medicines in people with advanced liver cancer that cannot be cured by surgery. It looks for safer treatment and signs that the medicines can shrink or control the cancer.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.